Facrbook
Follow @eaonc
Youtube
  • Home
  • About Us
    • Organizational Overview
    • Executive Leadership
    • Governance
    • Our Members
    • Scientific Planning and Review
    • Trial Monitoring
    • Operations
    • Biostatistics and Data Management
    • Collaborations
    • Active Clinical Trials
    • Find a Participating Institution
    • Scientific Achievements
    • Constitution
  • Scientific Programs
    • Cancer Control and Outcomes Program
    • Therapeutic Studies Program
    • Biomarker Sciences Program
  • Research Support
    • Research Support Committees
    • Mentoring Program
    • Training and Education
  • Research Cores
    • Central Biorepository and Pathology Facility
    • Imaging Core Laboratory
    • Leukemia Translational Science Center
    • Thoracic Malignancies Integrated Translational Science Center
  • Resources
    • Active Clinical Trials: Resources
    • Group Meetings
    • Comis Translational Science Symposium
    • NCI-MATCH / EAY131 for Researchers
    • Publications
    • ECOG Performance Status
    • ECOG-ACRIN Sample Tracking System
    • CIRB
    • Medidata Rave®
    • TRIAD™
    • SOAPP
    • PrECOG
    • Related Websites
    • Document Library
  • Patients
    • Myths and Facts
    • External Resources and Links
    • Active Clinical Trials: Resources
  • News and Info
    • Advocacy Blog
    • Member Blog
    • Press Releases
  • Contact Us
    • Donations
    • Locations
    • Office of Communications
    • Find a Participating Institution
    • Principal Investigators
Follow @eaonc

Active Clinical Trials: Resources

Numerous clinical trials are always open and enrolling patients in the ECOG-ACRIN Cancer Research Group, which focuses its research on adults 18 years of age and older who have or are at risk of developing cancer. This section of the website contains links to all materials that are publicly available to patients and researchers.

To access materials for a particular trial, click on the trial ID in the list below.

Cancer Type

Trial ID and Target Patient Population

Any Solid Tumor, Lymphoma, or Myeloma, or Cancer Type with No Standard Treatment Available NCI-MATCH / EAY131 – Eligibility Based on Genetic Testing
Brain EAF151 – Glioblastoma, Recurrent
Breast EA1131 – Triple-Negative, Including Men
EA1151 / TMIST – Screening Mammography
EA1181 / CompassHER2 pCR – HER2-Positive
EA1183 / FEATURE – Bone-dominant, Metastatic
EAI142 – Newly Diagnosed, Advanced
EAZ171 – Neuropathy in Black Women
6694 – Imaging of Women in the Alliance A011104 Trial
Cancer Care Delivery Research EAQ171CD – Any Cancer, Stop-Smoking Counseling
Cancer Control EA9131 – Acute Promyelocytic Leukemia
and Survivorship E1Q11 / EROS – Any Cancer, Reproductive Health Planning
EAQ172 – Any Cancer, Treatment of Lung Inflammation
EAQ191 / CARISMA – Blood Pressure Management
Gastrointestinal EA2142 – Pancreas or Gastrointestinal Tract, Advanced
EA2165 – Anal
EA2174 – Esophagus
EA2176 – Anal (Treatment-Naïve)
EA2182 / DECREASE – Anal, Squamous Cell
EA2183 – Esophagus and Gastric
EA2185 – Surveillance of Non-Cancerous Pancreas Cysts
EA2186 / GIANT – Pancreatic, Advanced (Aged 65+)
EA2187 – Bile Duct (Cholangiocarcinoma), Advanced
EA2197 / OPT-IN – Gallbladder
7151 – Detection of Colon Cancer (By Invitation Only)
Genitourinary EA8134 / InPACT – Penis
EA8143 / PROSPER RCC – Kidney
EA8153 / CHAARTED2 – Prostate, Hormone-Sensitive
EA8171 – Prostate (Imaging/Treatment Planning)
EA8183 / ERADICATE – Prostate (Post Prostatectomy)
EA8185 / INSPIRE – Bladder, Node Positive
EA8191 / INDICATE – Prostate (Recurrence)
Gynecologic None at this time
Head and Neck EA3132 – p53-Mutated Squamous Cell, After Surgery
EA3161 – Oropharyngeal Squamous Cell Carcinoma (Throat), HPV-Positive
EA3163 – Nose and Sinus, Squamous Cell
EA3191 – Recurrent Squamous Cell, High Risk Features
Leukemia EA9131 – Acute Promyelocytic Leukemia
EA9152 – Acute Lymphoblastic Leukemia (T-cell or B-cell)
EA9161 – Chronic Lymphocytic Leukemia
EA9171 – Myeloid Leukemia
EA9181 – Acute Lymphoblastic Leukemia (BCR-ABL-positive)
NHLBI-MDS / The National MDS Study – Observation of Myelodysplastic Syndromes
Lymphoma EA4151 – Mantle Cell
EA4181 – Mantle Cell
E4412 – Hodgkin
PrE0404 – Mantle Cell
PrE0405 – Mantle Cell
Melanoma EA6134 / DREAMseq – Advanced, BRAFV600-Mutated
EA6141 – Advanced
EA6174 / STAMP – Merkel Cell, After Surgery
EA6183 – Cutaneous or Unknown Primary
EA6191 / BAMM2 – Advanced, BRAF V600E/K
EA6192 / PET-Stop – Advanced
Myeloma EAA173 / DETER-SMM – Smoldering Myeloma
EAA181 / EQUATE – Multiple Myeloma (Newly Diagnosed)
Prevention EAZ171 – Neuropathy in Black Women
Thoracic (Lung Cancer) EA5162 – Non-Small Cell, Advanced
EA5163 / S1709 / INSIGNA –  Non-Small Cell, Advanced
EA5181 – Non-Small Cell, Unresectable
EA5182 – Non-Small Cell, Advanced
EA5191 – Non-Squamous Non-Small Cell
E4512, an ALCHEMIST trial – Non-Small Cell, Early
Lung-MAP – Squamous Cell. Previously Treated
4703 / DECAMP-1 – Detection in Military Personnel
4704 / DECAMP-2 – Screening of Military Personnel
6697 – Imaging of Patients in the RTOG 1106 Trial

© 2012-2020 ECOG-ACRIN Cancer Research Group. All rights reserved.  |  Disclaimer